EA Announces Research Acceleration Grant Focusing on Kinase Mutations and Cancer
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Expression Analysis has announced a jointly sponsored research grant for up to eight American Cancer Society Grantees to investigate and draw parallels between specific cancers and recurring mutations in specific kinases, using targeted genome sequencing.
Each grantee will provide up to 12 human samples (six disease, six control) to EA for enrichment using Agilent Technologies’ SureSelect Human Kinome Kit. EA will perform the sequencing of the kinome of each sample at no cost, using Illumina’s Genome Analyzeriix technology, reagents and flow cells. EA will then provide analysis of sequence data along with final reports and raw sequence data.
“Through this grant, Illumina, Agilent and Expression Analysis seek to help the cancer research community apply the power of next generation sequencing to advancing our understanding of the genetic variants associated with kinase mutations,” said David Bentley, chief scientist at Illumina.
Bentley continued, “Because they play an essential role in cell signaling pathways, kinases are intimately involved in cancer cell growth, proliferation and survival. Along with their direct regulators, these proteins are among the most frequently mutated oncogenes and tumor suppressors. Greater knowledge in this crucial area could help us make important new headway in understanding, preventing and treating cancer.”
“Genomic discoveries are paramount to ultimately uncovering underlying mechanisms of cancer development, and we believe this collaboration between EA, Illumina and Agilent will work to further the progress of these discoveries,” said Steve McPhail, President and CEO of EA.
McPhail continued, “EA is committed to providing cancer researchers with industry-leading services that help accelerate the pace of cancer research. The research community has widely adopted Illumina’s sequencing technology and Agilent’s SureSelect target enrichment products, so it made perfect sense for our three companies to come together and offer this program.”
Each grantee will provide up to 12 human samples (six disease, six control) to EA for enrichment using Agilent Technologies’ SureSelect Human Kinome Kit. EA will perform the sequencing of the kinome of each sample at no cost, using Illumina’s Genome Analyzeriix technology, reagents and flow cells. EA will then provide analysis of sequence data along with final reports and raw sequence data.
“Through this grant, Illumina, Agilent and Expression Analysis seek to help the cancer research community apply the power of next generation sequencing to advancing our understanding of the genetic variants associated with kinase mutations,” said David Bentley, chief scientist at Illumina.
Bentley continued, “Because they play an essential role in cell signaling pathways, kinases are intimately involved in cancer cell growth, proliferation and survival. Along with their direct regulators, these proteins are among the most frequently mutated oncogenes and tumor suppressors. Greater knowledge in this crucial area could help us make important new headway in understanding, preventing and treating cancer.”
“Genomic discoveries are paramount to ultimately uncovering underlying mechanisms of cancer development, and we believe this collaboration between EA, Illumina and Agilent will work to further the progress of these discoveries,” said Steve McPhail, President and CEO of EA.
McPhail continued, “EA is committed to providing cancer researchers with industry-leading services that help accelerate the pace of cancer research. The research community has widely adopted Illumina’s sequencing technology and Agilent’s SureSelect target enrichment products, so it made perfect sense for our three companies to come together and offer this program.”
